Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: C09CA04

Ifirmasta (previously Irbesartan Krka)(irbesartan hydrochloride)

Hypertension

Marketing Authorisation Holder: Krka, d.d., Novo mesto

EMA Authorisation: 01/12/2008

INN: irbesartan

Indication

Treatment of essential hypertension. Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Ifirmasta (previously Irbesartan Krka) — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.